VOLGA: impact of ctDNA clearance on survival outcomes in bladder cancer

(1:27)

ctDNA clearance linked to improved outcomes in MIBC neoadjuvant therapy: results from VOLGA study

(1:12)

ctDNA-guided immunotherapy in MSI-H stage III colon cancer

(2:28)

Circulating tumor DNA: a new frontier in colorectal cancer -- Dr. Stacey Cohen

(47:42)

Enhancing ctDNA monitoring for prime time use in high-risk melanoma

(2:47)

CtDNA Clearance With Neoadjuvant Durvalumab Plus Tremelimumab and EV for Cisplatin-Ineligible MIBC

(3:42)

ctDNA and MRD | 2023 Best of GI Cancer Conference

(58:52)

2021 West Oncology | Gastrointestinal Cancers | ctDNA Analysis in Colorectal Cancer

(15:23)

The emerging role of ctDNA as a predicative marker in dMMR/MSI-H colorectal cancer

(1:57)

NRG-GI005: ctDNA predicts adjuvant chemo in stage II colon cancer

(4:30)

Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC

(3:5)

Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma

(1:48)

Exploring the role of personalized ctDNA monitoring in high-risk melanoma

(3:12)

ctDNA monitoring to assess clinical outcomes in mCRC treated with front-line chemotherapy

(5:30)

ctDNA and MRD: Who, When, and Then What? | 2022 Evolution Conference

(46:53)

Understanding ctDNA Tumor Fraction in Advanced NSCLC

(20:2)

Examining the role of tissue-agnostic ctDNA monitoring in breast cancer

(2:8)

COBRA: ctDNA to help decide which patients with colon cancer will benefit from adjuvant chemotherapy

(4:31)

Evaluating tumor response with ctDNA

(1:39)

ctDNA Shows Promise for Assessing Lung Cancer Treatment Response

(5:50)